New crown drug Paxlovid will land in Beijing community, related distribution companies are expected to benefit
Read Time:1 Minute, 1 Second
Jiao Hong, director of the State Drug Administration in Beijing research and inspection of the new coronavirus vaccine and treatment drug production and circulation enterprises work situation, stressed that continue to strengthen the production and supply, circulation and use of all aspects, the whole chain of dynamic supervision, and effectively safeguard the quality and safety of drugs, powerful service epidemic prevention and control of the overall situation.
The company’s main goal is to provide the best possible service to the community. All said that they have now received notice to attend training on the application of the antiviral drug nematovir/ritonavir tablets (Paxlovid), but the drug has not yet been distributed to.
Among the relevant listed companies.
China Pharmaceutical and Pfizer signed an agreement under which the company will be responsible for the import and distribution of Pfizer’s new coronavirus treatment drug nematovir tablets/ritonavir tablets (Paxlovid) in the mainland China market during the term of the agreement, which ends on November 30, 2023.
Xinhua Pharmaceutical and Real Bio signed the Strategic Cooperation Agreement, in which Real Bio agreed to be the manufacturer and distributor of products owned by Xinhua Pharmaceutical, including Azivudine, in China and other countries as agreed by both parties.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating